article thumbnail

J&J’s Christopher Whelan on How—and Why—13 Companies Teamed up to Tackle Proteomics

BioSpace

The Pharma Proteomics Project isn’t the first precompetitive collaboration between pharma companies, but it’s one of the largest. Members recently published associations they’ve uncovered in UK Biobank data.

article thumbnail

Digitalising drug discovery

pharmaphorum

The oceans of health data out there can be overwhelming for pharma companies to manage – but if extracted correctly, the prospect to develop drugs from scratch in as little as a year is very real, says Lifebit CEO, Dr Maria Chatzou Dunford. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

As part of the US government’s Cancer Moonshot initiative, a Cancer Moonshot Biobank was launched that asked participants to donate biospecimens and associated health information to aid research. The focus of research projects on gathering data, particularly genetic data, is now common place in nationwide health-focused initiatives.

article thumbnail

Post-COVID-19 cognitive impairment: a new target for drug development?

Drug Discovery World

Structural MRI data from the UK Biobank cohort found reductions in global brain size, particularly reduced grey matter thickness in the orbitofrontal cortex and parahippocampal gyrus, among participants who had had Covid-19, an average of 141 days before scanning 11. 2020, doi: 10.1016/j. 2020.08.028. G Douaud et al., 697–707, Apr.

article thumbnail

Fibrosis research: Advances and challenges 

Drug Discovery World

PW: Through our exclusive access to one of the world’s largest fibrosis tissue biobanks, we have correlated disease progression to gene expression data, enabling us to discover novel targets on the pathway that drives the advanced stages of fibrotic disease. To be successful, biotech companies really need to be ahead of big pharma.